Markt für Carbapenem-basierte Antibiotika – Erkenntnisse aus globaler und regionaler Analyse – Prognose bis 2031

  • Report Code : TIPRE00027228
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 180
Buy Now

Es wird erwartet, dass die Marktgröße für Carbapenem-basierte Antibiotika von 3.964,57 Millionen US-Dollar im Jahr 2021 auf 5.346,62 Millionen US-Dollar im Jahr 2028 wachsen wird; Es wird geschätzt, dass sie zwischen 2021 und 2028 mit einer jährlichen Wachstumsrate von 4,4 % wachsen wird.

Carbapeneme sind atypische β-Lactam-Antibiotika mit breiterer antibakterieller Aktivität. Carbapenem-basierte Antibiotika können viele grampositive, gramnegative aerobe und anaerobe Bakterien bekämpfen. Darüber hinaus sind Antibiotika auf Carbapenem-Basis gegenüber den meisten β-Lactamasen stabil. Daher sind sie als empirische Monotherapie für verschiedene schwerwiegende Erkrankungen wie neutropenische Infektionen und intraabdominale Infektionen indiziert.

Strategische Erkenntnisse


Die steigende Prävalenz Infektionen mit gramnegativen Bakterien und die zunehmende Produktion von Generika fördern das Wachstum des Marktes für Carbapenem-basierte Antibiotika. Der langwierige und teure Prozess der Antibiotikaentwicklung hemmt jedoch das Marktwachstum.

Globaler Markt für Carbapenem-basierte Antibiotika

< p>

Markteinblicke
Steigende Prävalenz gramnegativer bakterieller Infektionen

Gramnegative bakterielle Infektionen, wie z. B. Harnwegsinfektionen (HWI), Lungenentzündung, Blutkreislaufinfektionen, Wund- oder Operationsstelleninfektionen und Meningitis erkranken häufig bei Patienten während ihres Krankenhausaufenthalts. Diese Infektionen werden allgemein als im Krankenhaus erworbene Infektionen (HAI) bezeichnet. Infektionen wie Harnwegsinfektionen und Lungenentzündung kommen bei Patienten auf Intensivstationen häufig vor. Nach Angaben des US-amerikanischen National Healthcare Safety Network werden 30 % der HAI durch gramnegative Bakterien verursacht, etwa 45 % sind auf Harnwegsinfektionen zurückzuführen und etwa 47 % sind auf eine beatmungsassoziierte Pneumonie (VAP) zurückzuführen. Die Prävalenz von Infektionskrankheiten, die durch gramnegative Bakterien verursacht werden, nimmt rapide zu.

Darüber hinaus sind gramnegative bakterielle Infektionen resistent gegen mehrere Medikamente und haben eine bessere Resistenz gegen verfügbare entwickelt Antibiotika. Antibiotikaresistenzen (AMR) sind zu einer globalen Bedrohung für die moderne Medizin geworden. Daher ist für die klinischen Isolate eine ständige Überwachung neuer Trends erforderlich. Eine Gruppe von Forschern in Lettland, Europa, hat das Fortschreiten der Antibiotikaresistenz bei verschiedenen gramnegativen Bakterien untersucht. Laut dem von ihnen im Juni 2021 im MDPI-Journal veröffentlichten Forschungsartikel waren Carbapenem-basierte Antibiotika wie Meropenem und Ertapenem am wirksamsten gegen gramnegative Bakterien und wiesen eine Resistenzrate von 3 % bzw. 5,4 % auf. Diese Antibiotika sind weltweit zur Behandlung gramnegativer Bakterien anerkannt. Daher wird geschätzt, dass die hohe Nachfrage nach Carbapenem-basierten Antibiotika in den kommenden Jahren wahrscheinlich anhalten wird.

Laut den Centers for Disease Control and Prevention (CDC) Die COVID-19-Pandemie führte im Jahr 2020 zu einem Anstieg der HAI-Fälle. Die Zahl der Krankenhauseinweisungen hat weltweit zugenommen, was das Risiko einer VAP als Sekundärinfektion für COVID-19-Patienten erhöht hat. Dies hat zu einer erhöhten Nachfrage nach Carbapenem-basierten Antibiotika geführt, was den Markt erheblich unterstützt.

Typbasierte Einblicke

Die Carbapenem-basierten Der Antibiotikamarkt ist nach Typ in Meropenem, Doripenem, Imipenem, Tebipenem und andere unterteilt. Das Segment „Andere“ hatte im Jahr 2021 den größten Anteil am Markt für Carbapenem-basierte Antibiotika und wird im Prognosezeitraum voraussichtlich die höchste CAGR auf dem Markt verzeichnen. Die wachsenden Entwicklungen bei Carbapenem-basierten Antibiotika dürften das Marktwachstum in der Zukunft vorantreiben.

Marktanteil von Carbapenem-basierten Antibiotika nach Typ – 2021 und 2028

Indikationsbasierte Erkenntnisse

Durch Indikation, die Der Markt für Antibiotika auf Carbapenem-Basis ist in bakterielle Meningitis, akute Beckeninfektionen, Atemwegsinfektionen, intraabdominelle Infektionen, Harnwegsinfektionen und andere unterteilt. Das Segment „Andere“ hatte im Jahr 2021 den größten Anteil am Markt für Carbapenem-basierte Antibiotika und wird im Prognosezeitraum voraussichtlich die höchste CAGR auf dem Markt verzeichnen. Die Ungewissheit über bakterielle Infektionen treibt die Nachfrage nach Carbapenem-basierten Antibiotika voran, was voraussichtlich das Marktwachstum in den kommenden Jahren vorantreiben wird.

Vertriebskanalbasierte Einblicke< /h3>

Nach Vertriebskanälen ist der Markt für Carbapenem-basierte Antibiotika in Einzelhandelsapotheken, Online-Apotheken und Krankenhausapotheken unterteilt. Das Segment der Krankenhausapotheken hatte im Jahr 2021 den größten Anteil am Markt für Carbapenem-basierte Antibiotika und wird im Prognosezeitraum voraussichtlich die höchste CAGR auf dem Markt verzeichnen.

 

Bio-Strategien wie die Einführung neuer Produkte werden häufig von Unternehmen übernommen, um ihr Produktportfolio auf dem Markt zu erweitern. Darüber hinaus haben die Unternehmen verschiedene anorganische Strategien umgesetzt, beispielsweise Fusionen und Übernahmen sowie Partnerschaften. Beispielsweise brachte Gland Pharma Limited im Mai 2021 in Zusammenarbeit mit Dr. Reddy's Laboratories Ltd Ertapenem zur Injektion, 1 g/Durchstechflasche, auf den Markt, ein therapeutisches Äquivalent zur generischen Version von INVANZ (Ertapenem zur Injektion) zur Injektion, 1 g/Durchstechflasche von der US-amerikanischen Food and Drug Administration (USFDA) zugelassen.

Unternehmensprofile

  • Pfizer Inc.
  • Retter Lifetec
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Merck & Co., Inc.
  • Gland Pharma Limited
  • Aurobindo Pharma Ltd
  • DAEWOONG PHARMACEUTICAL CO.,LTD
  • Iterum Therapeutics plc
  • ACS Dobfar SpA
  • Spero Therapeutics
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What are the carbapenem-based antibiotics?

Carbapenems are type of atypical β-lactam antibiotics that have wider antibacterial activity. Carbapenem-based antibiotics can cover many gram-positive, gram-negative aerobic, anaerobic bacteria. Additionally, carbapenem-based antibiotics are stable to most β-lactamases and hence, are indicated as empiric monotherapy for various serious conditions such as neutropenic infections and intra-abdominal infections.

What are the driving factors for the global carbapenem-based antibiotics market across the world?

The factors that are driving the growth of market are growing rising prevalence of gram-negative bacterial infections and increasing production of generic drugs fuel the growth of the market. However, the tedious and expensive process of antibiotic development, as well as approval, is the major factor hindering the market growth.

Who are the major players in market the carbapenem-based antibiotics market?

The carbapenem-based antibiotics market majorly consists of the players such as Pfizer Inc.; Savior Lifetec; Sumitomo Dainippon Pharma Co., Ltd.; Merck & Co., Inc.; Gland Pharma Limited; Aurobindo Pharma Ltd; Daewoong Pharmaceutical Co.,Ltd; Iterum Therapeutics plc; ACS Dobfar S.p.A, and Spero Therapeutics among others.

Which segment is dominating the carbapenem-based antibiotics market?

The carbapenem-based antibiotics market is analyzed in the basis of type, indication, and distribution channel. Based on type, is segmented into meropenem, doripenem, imipenem, tebipenem, and others. The others segment held the largest share of the market, and it is anticipated to register the highest CAGR. Based indication, the market is segmented as bacterial meningitis, acute pelvic infections, respiratory tract infections, intra-abdominal infections, urinary tract infections, and others. The others segment held the largest share of the market, and it is estimated to register the highest CAGR. And based on distribution channel, the market is divided into retail pharmacies, online pharmacies, and hospital pharmacies. The hospital pharmacies segment held the largest share of the market, and it is estimated to register the highest CAGR.

The List of Companies - Carbapenem Based Antibiotics Market

  1. Pfizer Inc.
  2. Savior Lifetec
  3. Sumitomo Dainippon Pharma Co., Ltd.
  4. Merck & Co., Inc.
  5. Gland Pharma Limited
  6. Aurobindo Pharma Ltd
  7. Daewoong Pharmaceutical Co.,Ltd,
  8. Iterum Therapeutics plc
  9. ACS Dobfar S.p.A
  10. Spero Therapeutics

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports